ACP
KNTE

Acuta Capital Partners’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Acuta Capital Partners’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,000
Closed -$31.3K – 44
2023
Q1 		$31.3K Hold
5,000
– – 0.02% 34
2022
Q4 		$30.5K Hold
5,000
– – 0.02% 33
2022
Q3 		$60K Buy
+5,000
New +$65.4K 0.03% 44

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acuta Capital Partners's KNTE Position: Q2 2023 in Review

Acuta Capital Partners sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2023, closing a stake of 5,000 shares — an estimated $31.3K sold.

Acuta Capital Partners first reported a position in KNTE in Q3 2022 and held it in 3 quarters. The position peaked at $60K in Q3 2022. 72 funds tracked by Wall St. Rank hold KNTE as of Q2 2023.

  • Acuta Capital Partners reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Acuta Capital Partners sold 5,000 Kinnate Biopharma Inc. Common Stock shares in Q2 2023, an estimated $31.3K.
  • Acuta Capital Partners first reported a position in Kinnate Biopharma Inc. Common Stock in Q3 2022 and held it in 3 quarters.
  • Acuta Capital Partners's Kinnate Biopharma Inc. Common Stock position peaked at $60K in Q3 2022.
  • 72 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2023.

Based on Acuta Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.